Pamlico BioPharma Elects Dr. Mark Corrigan To Its Board of Directors

OKLAHOMA CITY, Aug. 13, 2015 /PRNewswire/ -- Pamlico BioPharma, Inc., a research-stage biopharmaceutical company developing fully human monoclonal antibody (hmAb) therapeutics and diagnostics for infectious disease and cancer, announced today the election of Mark H. N. Corrigan, M.D., to the Company's Board of Directors. Dr. Corrigan is a seasoned life sciences executive with broad operational and clinical development experience at leading pharmaceutical and biotechnology companies. His election to the Pamlico Board is effective immediately.

"Mark brings extensive experience in clinical research and development of novel therapeutic agents that have successfully navigated clinical testing and FDA filing," stated Clayton Duncan, Pamlico's Chairman and CEO. "His knowledge, combined with his experience in guiding the growth of biopharma companies, will be vital as we continue to advance our lead programs through development and into clinical testing."

Pamlico's lead clinical program, PneumomAb, consists of serotype-specific human monoclonal antibodies against the predominant serotypes of Streptococcus pneumoniae (SPN) that account for over 70% of SPN infections. PneumomAb is currently in preclinical activities for both hmAb therapeutics and a companion point-of-care (POC) diagnostic for severe community-acquired pneumococcal pneumonia (SPN-CAP) and is anticipated to enter clinical testing in 2016. Pamlico is pursuing additional hard-to-treat infections using its RAPIDmAb platform, and the Company expects to announce further progress on its programs through 2015 and into 2016.

Dr. Corrigan commented, "I am excited to work with the leadership team at Pamlico and to contribute to their mission of addressing important pathogens with significant unmet clinical needs. The Company has demonstrated strong preclinical evidence that their RAPIDmAb platform offers an important therapeutic option for hard-to-treat diseases, while dramatically reducing costs and improving the speed of antibody discovery. I look forward to the progress of their lead program as it enters the clinic next year."

About Dr. Mark Corrigan

Dr. Corrigan is the former President and Chief Executive Officer of Zalicus, Inc., which in 2014 merged with EPIRUS Biopharmaceuticals, a developer of biosimilar agents for global markets. He currently serves as Chairman of EPIRUS' Board. Previously, Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan served on the Board of Directors for Cubist Pharmaceuticals, chairing the Scientific and Clinical Oversight Committee, and of Avanir Pharmaceuticals prior to these companies' acquisitions by Merck and Otsuka Holdings, respectively. Dr. Corrigan presently serves on the Board of Cardiome Pharma and Synereca Pharmaceuticals. Dr. Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

About Pamlico BioPharma, Inc.

Pamlico BioPharma develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. Pamlico has used its proprietary RAPIDmAb platform to isolate high-affinity antibodies to all 24 vaccine serotypes of Streptococcus pneumoniae, influenza, Varicella zoster, rabies virus, and other infectious diseases, with a speed and cost advantage unprecedented in antibody discovery. Pamlico's lead program is focused on severe pneumonia caused by S. pneumoniae (SPN) and is developing hmAb therapeutics and a companion point-of-care (POC) diagnostic against the predominant serotypes that account for over 70% of SPN infections in pneumococcal community-acquired pneumonia. Pamlico and a major international health authority are collaborating on a laboratory diagnostic for serotype-surveillance of pneumococcal infection. Additional discovery programs are underway for Hepatitis B, human papillomavirus, tuberculosis, and other infectious disease and cancer targets. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and Emory University, and its first program is anticipated to enter clinical trials in 2016. For additional information, please visit

Justin Briggs
Investor Relations
Pamlico BioPharma
(405) 319-8166
[email protected]

Justin Jackson
Burns McClellan
(212) 213-0006
[email protected]

To view the original version on PR Newswire, visit:

SOURCE Pamlico BioPharma, Inc.